Apart from lifestyle interventions (such as smoking cessation, physical activity, and diet), the current cornerstone in atherosclerosis prevention is treating the dyslipidemia with statins and, to a lesser extent, with ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [7]. This evidence concerns the gene PCSK9 and atherosclerosis.